The Efficacy of Vitamin D Supplementation in Patients With Severe and Extremely Severe COVID-19

SARS-CoV2 Infection Clinical Trial

— COVID-VIT  

Official title:

The Efficacy of Vitamin D Supplementation in Patients With Severe and Extremely Severe COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05092698
• Other study ID #: COVID-VIT
• Status: Completed
• Phase: N/A
• Start date: May 1, 2020
• Est. completion date: January 31, 2022

Study information

• Verified date: November 2021
• Source: Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Despite the successful treatment of patients with moderate coronavirus disease 2019 (COVID-19), outcomes for patients with severe disease remain unsatisfactory. In this category of patients, the course of the disease is complicated by the development of acute respiratory distress syndrome (ARDS) and the need for mechanical ventilation in the intensive care unit (ICU). Mortality in this category of patients reaches 85%. The lack of effective treatment for COVID-19 has prompted scientists to look for new strategies to reduce the incidence and severity of COVID-19, disease progression, and mortality.

Disease severity and mortality rates due to COVID-19 infection are greater in the elderly and chronically ill patients, populations at high risk for vitamin D deficiency. Vitamin D plays an important role in immune function and inflammation.

A number of experimental studies have shown that stimulation of vitamin D receptors can improve the course of ARDS due to inhibition of the hyperimmune inflammatory response, regulation of the renin-angiotensin system, modulation of neutrophil activity, maintenance of the integrity of the pulmonary epithelial barrier and stimulation of epithelial repair, as well as by reducing hypercoagulation.

Several studies on ICU patients have reported that low vitamin D (25(OH)D) concentrations are associated with a higher risk of negative outcomes such as death, organ failure, prolonged mechanical ventilation, a higher rate of ventilation-associated pneumonia, and sepsis.

While the available evidence to-date, from largely poor-quality observational studies, may be viewed as showing a trend for an association between low serum 25(OH)D levels and COVID-19 related health outcomes, this relationship was not found to be statistically significant. Calcifediol supplementation may have a protective effect on COVID-19 related ICU admissions.

Description:

The aim of the study is to evaluate the efficacy of vitamin D (cholecalciferol) supplementation in patients with severe and extremely severe disease caused by the SARS-CoV-2 virus, admitted to an ICU of the COVID-center on the first day and in dynamics until discharge from the hospital or death. Patients with vitamin D deficiency [25-hydroxyvitamin D (25(OH)D) ≤ 30 ng/ml] will be randomized to two groups: 1 - patients will receive 60,000 IU of cholecalciferol supplementation; 2 - patients will receive matched placebo.

The demographic and clinical data will be collected. Laboratory data (hemoglobin, lymphocytes, neutrophil to lymphocyte ratio, D-dimer level, Interleukin-6, procalcitonin, ferritin, glucose level, high-sensitive troponin Т, vitamin D level (25(OH)D), acid-base balance, signs of a secondary bacterial infection, immunogram, Von Willebrand factor antigen and Instrumental data (CT-scan, Electrocardiography, echocardiography, arterial and venous ultrasound investigation) will be analysed. The frequency of complications, duration of mechanical ventilation, length of stay in the ICU and in the hospital, and mortality will be evaluated.

This study is single-centre prospective randomized placebo-controlled trial.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 110
• Est. completion date: January 31, 2022
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• all patients with COVID-19 admitted to the ICU with vitamin D deficiency [25-hydroxyvitamin D (25(OH)D) = 30 ng/ml]

Exclusion Criteria:

• less than 24 hours in ICU by any reason

• chronic decompensated disease with extrapulmonary organ dysfunction (tumour progression, liver cirrhosis, congestive heart failure) with a life expectancy of less than 48 hours

• atonic coma

• allergic reaction on cholecalciferol or herbal oil

Related Conditions & MeSH terms

• COVID-19
• SARS-CoV2 Infection

Intervention

Dietary Supplement:
• Vitamin D (cholecalciferol)
Patients will receive 60,000 IU of cholecalciferol dissolved in 45 ml herbal oil orally or via feeding tube after serum Vitamin D concentrations measurement followed by the same dose of cholecalciferol weekly and 5,000 IU of cholecalciferol (two drops) daily until discharge or death.
• Herbal oil
Patients will receive 45 ml of herbal oil orally or via feeding tube after serum Vitamin D concentrations measurement followed by the same dose of pure herbal oil weekly and two drops of herbal oil daily until discharge or death.

Locations

Country	Name	City	State
Russian Federation	Federal Research Clinical Center of Federal Medical & Biological Agency	Moscow

Sponsors (1)

Lead Sponsor	Collaborator
Federal Research Clinical Center of Federal Medical & Biological Agency, Russia

Country where clinical trial is conducted

Russian Federation, 

References & Publications (4)

Bassatne A, Basbous M, Chakhtoura M, El Zein O, Rahme M, El-Hajj Fuleihan G. The link between COVID-19 and VItamin D (VIVID): A systematic review and meta-analysis. Metabolism. 2021 Jun;119:154753. doi: 10.1016/j.metabol.2021.154753. Epub 2021 Mar 24. — View Citation

Bychinin MV, Klypa TV, Mandel IA, Andreichenko SA, Baklaushev VP, Yusubalieva GM, Kolyshkina NA, Troitsky AV. Low Circulating Vitamin D in Intensive Care Unit-Admitted COVID-19 Patients as a Predictor of Negative Outcomes. J Nutr. 2021 Aug 7;151(8):2199-2205. doi: 10.1093/jn/nxab107. — View Citation

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28. — View Citation

Kong J, Zhu X, Shi Y, Liu T, Chen Y, Bhan I, Zhao Q, Thadhani R, Li YC. VDR attenuates acute lung injury by blocking Ang-2-Tie-2 pathway and renin-angiotensin system. Mol Endocrinol. 2013 Dec;27(12):2116-25. doi: 10.1210/me.2013-1146. Epub 2013 Nov 6. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	?omplete blood count	?omplete blood count	Change from baseline on day 5 during ICU treatment
Primary	?omplete blood count dynamics 1	?omplete blood count	Change from baseline on day 10 during ICU treatment
Primary	?omplete blood count dynamics 2	?omplete blood count	Change from baseline on day 15 during ICU treatment
Primary	?omplete blood count dynamics 3	?omplete blood count	Change from baseline on day 21 during ICU treatment
Primary	C-reactive protein	Concentration of C-reactive protein	Change from baseline on day 5 during ICU treatment
Primary	C-reactive protein 1	Concentration of C-reactive protein	Change from baseline on day 10 during ICU treatment
Primary	C-reactive protein 2	Concentration of C-reactive protein	Change from baseline on day 15 during ICU treatment
Primary	C-reactive protein 3	Concentration of C-reactive protein	Change from baseline on day 21 during ICU treatment
Primary	Von Willebrand factor antigen	Concentration of Von Willebrand factor antigen	Change from baseline on day 7 during ICU treatment
Primary	Thrombotic complications	Arterial or venous thrombotic complications	60 days
Primary	Immunogram	The amount of NKT cells (CD3+CD56+CD16+), NK cells (CD3-CD56+CD16+)	Change from baseline on day 7 during ICU treatment
Primary	Proinflammatory marker	Concentration of D-dimer	Change from baseline on day 5 during ICU treatment
Primary	Proinflammatory marker 1	Concentration of D-dimer	on day 10 during ICU treatment
Primary	Proinflammatory marker 2	Concentration of D-dimer	on day 15 during ICU treatment
Primary	Proinflammatory marker 3	Concentration of D-dimer	on day 21 during ICU treatment
Primary	inflammatory marker	Concentration of Interleukin-6	Change from baseline on day 5 during ICU treatment
Primary	inflammatory marker 1	Concentration of Interleukin-6	Change from baseline on day 10 during ICU treatment
Primary	inflammatory marker 2	Concentration of Interleukin-6	Change from baseline on day 15 during ICU treatment
Primary	inflammatory marker 3	Concentration of Interleukin-6	Change from baseline on day 21 during ICU treatment
Primary	Infection marker	Concentration of Procalcitonin	Change from baseline on day 5 during ICU treatment
Primary	Infection marker 1	Concentration of Procalcitonin	Change from baseline on day 10 during ICU treatment
Secondary	Mortality	The dead and survived patients ratio	60 days
Secondary	Mechanical ventilation duration	The amount of mechanical ventilation days	30 days
Secondary	Non-invasive Mechanical ventilation duration	The amount of Non-invasive mechanical ventilation days	30 days
Secondary	Length of stay in the ICU	The amount of day of ICU treatment	60 days
Secondary	Length of stay in the hospital	The amount of day of hospital treatment	60 days
Secondary	Infection complications	The amount of Infection complications	60 day